Apoptosis: a novel therapeutic tool?

Bibliography

• PETER ME, HEUFELDER AE, HENGARTNER MO: Ad-vanced in apoptosis research. Proc. Natl. Acad. ScL USA (1997) 94:12736–12737.
   PubMed Web of Science ®Google Scholar
• KERR JF, WYLLIE AH, CURRIE AR: Apoptosis: a basic bio-logical phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer (1972) 26:239–258.
   PubMed Web of Science ®Google Scholar
• •Original paper wherein programmed cell death is first de-scribed and the term apoptosis is introduced.
   Google Scholar
• KERR JFR, WINTERFORD CM, HARMON BV: Apoptosis: its significance in cancer and cancer therapy. Cancer (1994) 73:2013–2026.
   PubMed Web of Science ®Google Scholar
• •A good review of how apoptosis plays a role in cancer ther-apy strategies written by one of the foremost researchers in the field.
   Google Scholar
• FISHER DE: Apoptosis in cancer therapy: crossing the threshold. Cell (1994) 78:539–542.
   PubMed Web of Science ®Google Scholar
• DENMEADE SR, UN XS, ISAACS JT: Role of programmed (apoptotic) cell death during the progression and ther-apy of prostate cancer. Prostate (1996) 28:251–265.
   PubMed Web of Science ®Google Scholar
• ••This paper discusses and diagrams apoptosis as a countercycle to the cell cycle. There is also a flow chart of the apop-totic process showing reversible steps that may be influ-enced through pharmacological and/or genetic manipulation versus those steps that are irreversible.
   Google Scholar
• TANG DG, PORTER AT: Target to apoptosis: a hopeful weapon for prostate cancer. Prostate (1997) 32:284–293.
   PubMed Web of Science ®Google Scholar
• MAZARAKIS ND, EDWARDS AD, MEHMET H: Apoptosis in neural development and disease. Arch. Dis. Child Fe-tal. Neonatal Ed. (1997) 77:F165–170.
   Web of Science ®Google Scholar
• HORTNAGL H, HELLWEG R: Pathophysiological aspects of human neurodegenerative diseases. Wien. Klin. Wo-chenschr. (1997) 109:623–635.
   PubMed Web of Science ®Google Scholar
• TATTON WG, CHALMERS-REDMAN RM, JU WY, WADIA J, TATTON NA: Apoptosis in neurodegenerative disor-ders: potential for therapy by modifying gene tran-scription. J. Neural Transm. (1997) 49(Suppl.):245–268.
   Google Scholar
• BREDESEN DE: Neural apoptosis. Ann. Neurol. (1995) 38:839–851.
   PubMed Web of Science ®Google Scholar
• ••This review paper has an excellent presentation of the vari-ous modulators of the apoptotic pathway and the role of apoptosis in neurodegenerative diseases.
   Google Scholar
• BROMME HJ, HOLTZ J: Apoptosis in the heart: when and why? Mol. Cell Biochem. (1996) 163/164:261–275.
   Google Scholar
• PIOT CA, PADMANABAN D, URSELL PC, SIEVERS RE, WOLFE CL: Ischemic preconditioning decreases apop-tosis in rat hearts in vivo. Circulation (1997) 96:1598–1604.
   PubMed Web of Science ®Google Scholar
• QUE FG, GORES GJ: Cell death by apoptosis: basic con-cepts and disease relevance for the gastroenterologist. Gastroenterology (1996) 110:1238–1243.
   PubMed Web of Science ®Google Scholar
• WATSON AJM: Necrosis and apoptosis in the gastroin-testinal tract. Gut (1995) 37:165–167.
   PubMed Web of Science ®Google Scholar
• BINET JL, MENTZ F, MERLE-BERAL H: Apoptosis in blood diseases. Hematol. Cell Ther. (1996) 38:253–264.
   PubMedGoogle Scholar
• HATFILL BJ, FESTER ED, STEYTLER JG: Apoptotic mega-karyocyte dysplasia in the myelodysplastic syndrome. Hematol. Pathol. (1992) 6:87–92.
   PubMedGoogle Scholar
• YUAN J, ANGELUCCI E, LUCARELLI G et al.: Accelerated programmed cell death (apoptosis) in erythroid pre-cursors of patients with severe beta-thalassemia (Cooley's Anemia). Blood (1993) 82:374–377.
   PubMed Web of Science ®Google Scholar
• MOUNTZ JD, GAUSE WC: Murine models of autoim-mune disease and Sjogren's syndrome. Curr. Opin. Rheumatol. (1993) 5:557–569.
   PubMedGoogle Scholar
• MOUNTZ JD, WU J, CHENG J, ZHOU T: Autoimmune dis-ease. A problem of defective apoptosis. Arthritis Rheum. (1994) 37:1415–1419.
   PubMed Web of Science ®Google Scholar
• ASHWELL JD, BERGER NA, CIDLOWSKI JA et al.: Coming to terms with death: apoptosis in cancer and immune development. Immunol Today (1994) 15:147–151.
   PubMedGoogle Scholar
• COTTER TG: Programmed to die: cell death in the im-mune system. Immunologist (1993) 1:181–184.
   Google Scholar
• TERAI C, KORNBLUTH RS, PAUZA CD et al.: Apoptosis as a mechanism of cell death in cultured T lymphocytes acutely infected with HIV-1. j Clin. Invest. (1991) 87:1710–1714.
   PubMed Web of Science ®Google Scholar
• GROUX H, TORPIER G, MONTE D et al.: Activation-induced death by apoptosis in CD4+ T cells from hu-man immunodeficiency virus-infected asymptomatic individuals. J. Exp. Med. (1992) 175:331–340.
   PubMed Web of Science ®Google Scholar
• BANDA NK, BERNIER J, KURAHARA DK et al: Crosslink-ing CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J. Exp. Med. (1992) 38:252–256.
   Google Scholar
• HOPWOOD D, LEVISON DA: Atrophy and apoptosis inthe cyclical human endometrium. J. Pathol (1976) 119:159–166.
   PubMed Web of Science ®Google Scholar
• CORNILLIE FJ, LAUWERYN JM, BROSENS IA: Normal hu-man endometrium. An ultrastructural survey. Gynecol Obstet. Invest. (1985) 20:113–129.
   PubMed Web of Science ®Google Scholar
• PARMLEY TH: Spontaneous cell death in the chorion laeve. Am. J. Obstet. Gynecol (1990) 162:1576–1583.
   PubMed Web of Science ®Google Scholar
• FINCH CE, TANZI RE: Genetics of aging. Science (1997) 278:407–411.
   PubMed Web of Science ®Google Scholar
• PAPAS, SKULACHEV VP: Reactive oxygen species, mito-chondria, apoptosis and aging. Mol. Cell. Biochem. (1997) 174:305–319.
   PubMed Web of Science ®Google Scholar
• TOMEI LD, COPE FO, BARR PJ: Apoptosis: aging and phenotypic fidelity. In: Apoptosis II: The Molecular Basis of Apoptosis in Disease. Tomei LD, Cope FO (Eds.), Cold Spring Harbor Laboratory Press, NY (1990377–396.
   Google Scholar
• KERR JFR, HARMON BV: Definition and incidence of apoptosis: an historical perspective. In: Apoptosis: The Molecular Basis of Cell Death. Tomei LD, Cope FO (Eds.), Cold Spring Harbor Laboratory Press, NY (1990:5–29.
   Google Scholar
• STELLAR H: Mechanisms and genes of cellular suicide. Science (1995) 267:1445–1449.
   PubMed Web of Science ®Google Scholar
• LIN XS, DENMEADE SR, ISAACS JT: The genetics of pro-grammed (apoptotic) cell death. Cancer Sun'. (1995) 25:173–194.
   PubMed Web of Science ®Google Scholar
• HALE AJ, SMITH CA, SUTHERLAND LC et al.: Apoptosis:molecular regulation of cell death. Eur. J. Biochem. (1996) 236:1–26.
   PubMedGoogle Scholar
• WYLLIE AH, KERR JF, CURRIE AR: Cell death: the signifi-cance of apoptosis. Int. Rev. Cytol. (1980) 68:251–306.
   PubMedGoogle Scholar
• HANDA H, HEGDE UP, KOTELNIKOV VM et al.: The ef-fects of 13-cis retinoic acid and interferon-a in chronic myelogenous leukemia cells in vivo in patients. Leuk. Res. (1997) 21:1087–1096.
   PubMed Web of Science ®Google Scholar
• WONG GHW, KASPAR RL, ZWEIGER G et al.: Strategies for manipulating apoptosis for cancer therapy with tu-mor necrosis factor and lymphotoxin. J. Cell. Biochem. (1996) 60:56–60.
   PubMed Web of Science ®Google Scholar
• LASTER SM, WOOD JG, GOODING LR: Tumor necrosisfactor can induce both apoptotic and necrotic forms of cell lysis. j Immunol. (1988) 141:2629–2634.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN A, TU Y, FADY C, VESCIO R, BERENSON J: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol. (1995) 162:248–255.
   PubMed Web of Science ®Google Scholar
• AMOS TA, LEWIS JL, GRAND FH et al.: Apoptosis in chronic myeloid leukaemia: normal responses by pro-genitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br. J. Haematol (1995) 91:387–393.
   PubMed Web of Science ®Google Scholar
• HARNEY JV, SEYMOUR CB, MURPHY DM et al. Variation in the expression of p53, c-myc, and bc1-2 oncopro-teins in individual patient cultures of normal urothe-lium exposed to cobalt 60 gamma-rays and © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6) /V-nitrosodiethanolamine. Cancer Epidemiol. Biomark-ers Prey. (1995) 4:617–625.
   PubMed Web of Science ®Google Scholar
• VINCENT PC: Apoptosis and the assessment of radia-tion injury. Stem Cells (Dayt) (1995) 13 (Suppl. 1) :153–164.
   Google Scholar
• MEYN RE: Apoptosis and response to radiation: impli-cations for radiation therapy. Oncology (1997) 11:349–365.
   PubMedGoogle Scholar
• •This paper discusses differences in apoptotic responses of cells following radiation. It also proposes methods to deter-mine if cells are likely to be sensitive to radiation-induced apoptosis and possible uses of sensitising agents.
   Google Scholar
• YOUNG AR: The sunburn cell. Photodermatology (1987) 4:127–134.
   PubMedGoogle Scholar
• DANNO K, HORIO T: Formation of UV-induced apopto-sis relates to the cell cycle. Br. J. Dermatol. (1982) 107:423–438.
   PubMed Web of Science ®Google Scholar
• MARTIN SJ, NEWMEYER DD, MATHIAS S et al.: Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis. EMBO J (1995) 14:5191–5200.
   PubMed Web of Science ®Google Scholar
• BUTTKETM, SANDSTROM PA: Oxidative stress as media-tor of apoptosis. Immunol. Today (1994) 15:7–10.
   PubMedGoogle Scholar
• CORCORAN GB, FIX L, JONES DP et al.: Apoptosis: mo-lecular control point in toxicity. Toxicol. Appl. Pharma-col. (1994) 128:169–181.
   PubMed Web of Science ®Google Scholar
• KYPRIANOU N, ISAACS JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 122:552–562.
   PubMed Web of Science ®Google Scholar
• KYPRIANOU N, ENGLISH HF, ISAACS JT: Programmed cell death during regression of the PC-82 human pros-tate cancer following androgen withdrawal. Cancer Res. (1991) 50:3748–3753.
   Web of Science ®Google Scholar
• KYPRIANOU N, ENGLISH HF, DAVIDSON NE, ISAACS JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. (1991) 51:162–166.
   PubMed Web of Science ®Google Scholar
• GOUGEON M-L, MONTAGNIER L: Apoptosis in AIDS. Sci-ence (1993) 260:1269–1270.
   PubMed Web of Science ®Google Scholar
• ZYCHLINSKI A, PREVOST MC, SANSONETTI PJ: Shigella flexneri induces apoptosis in infected macrophages. Nature (1992) 358:167–169.
   PubMed Web of Science ®Google Scholar
• ESOLEN LM, PARK SW, HARDWICK JM, GRIFFITH DE: Apoptosis as a cause of death in measles virus-infected cells. J. Virol. (1995) 69:3955–3958.
   PubMed Web of Science ®Google Scholar
• SHEN Y, SHENK TE: Viruses and apoptosis. Curr. Opin. Genet. Dev. (1995) 5:105–111.
   PubMedGoogle Scholar
• PETITO CK, ROBERTS B: Evidence of apoptotic cell death in HIV encephalitis. Am. J. Pathol. (1995) 146:1121–1130.
   PubMed Web of Science ®Google Scholar
• CANMAN CE, CHEN C-Y, LEE M-H, KASTAN MB: DNA damage responses: p53 induction, cell cycle perturba-tions, and apoptosis. Cold Spring Harbor Symp. Quant Biol. (1994) 54:277–286.
   Google Scholar
• SCHEPOTIN IB, SOLDENTAKOV V, BURAS RR etal.: Apop-tosis of human primary and metastatic colon adeno-carcinoma cell lines in vitro induced by 5-fluorouracil, verapamil, and hyperthermia. Anticancer Res. (1994) 14:1027–1031.
   Google Scholar
• VAN CUTSEM E: A glimpse of the future. New directionsin the treatment of colorectal cancer. Eur. J. Cancer. (1996) 32A\(Suppl. 5):S23–S27.
   Google Scholar
• KUNG AL, ZETTERBERG A, SHERWOOD SW, SCHIMKE RT:Cytotoxic effects of cell cycle phase specific agents: re-sults of cell cycle perturbations. Cancer Res. (1990) 50:7307–7317.
   PubMed Web of Science ®Google Scholar
• CREGAN SP, BOREHAM DR, WALKER PR, BROWN DL, MITCHEL RE: Modification of radiation-induced apop-tosis in radiation- or hyperthermia-adapted human lymphocytes. Biochem. Cell Biol (1994) 72:475–482.
   PubMed Web of Science ®Google Scholar
• FAIRBAIRN JJ, KHAN MW, WARD KJ et al.: Induction ofapoptotic cell DNA fragmentation in human cells after treatment with hyperthermia. Cancer Lett. (1995) 89:183–188.
   PubMed Web of Science ®Google Scholar
• FULLER KJ, ISSELS RD, SLOSMAN DO et al.: Cancer andthe heat shock response. Eur. J. Cancer (1994) 29A:1884–1891.
   Google Scholar
• FRIESEN C, HERR I, KRAMMER PH, DEBATIN KM: Involve-ment of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. (1996) 2:574–577.
   PubMed Web of Science ®Google Scholar
• CLEVELAND JL, IHLE JN: Contenders in FasL/TNF death signaling. Cell (1995) 81:479–482.
   PubMed Web of Science ®Google Scholar
• THATTE U, DAHANUKAR S: Apoptosis: clinical rele-vance and pharmacological manipulation. Drugs (1997) 54:511–532.
   PubMed Web of Science ®Google Scholar
• HACKER G, VAUX DL: The medical significance of physiological cell death. Med. Res. Rev. (1995) 15:299–311.
   PubMed Web of Science ®Google Scholar
• BARR PJ, TOMEI LD: Apoptosis and its role in human disease. Biotechnology (1994) 12:487–492.
   PubMed Web of Science ®Google Scholar
• ROWAN S, FISHER DE: Mechanisms of apoptotic cell death. Leukemia (1997) 11:457–465.
   PubMed Web of Science ®Google Scholar
• RUDIN CM, THOMPSON CB: Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu. Rev. Med. (1997) 48:267–281.
   PubMed Web of Science ®Google Scholar
• DIXON SC, SORIANO BJ, LUSH RM, BORNER MM, FIGG WD: Apoptosis: its role in the development of malig-nancies and its potential as a novel therapeutic tool. Ann. Pharmacother. (1997) 31:76–82.
   PubMed Web of Science ®Google Scholar
• FESUS L, DAVIES PJA, PIACENTINI M: Apoptosis: molecu-lar mechanisms in programmed cell death. Eur. J. Cell Biol. (1991) 56:170–177.
   PubMed Web of Science ®Google Scholar
• CARSON DA, RIBEIRO JM: Apoptosis and disease. Lancet (1993) 341:1251–1254.
   PubMed Web of Science ®Google Scholar
• ARENDS MJ, WYLLIE AH: Apoptosis: mechanisms and roles in pathology. mt. Rev. Exp. Pathol. (1991) 32:223–254.
   PubMedGoogle Scholar
• MCCONKEY DJ, ORRENIUS S: The role of calcium in theregulation of apoptosis. Biochem. Biophys. Res. Comm. (1997) 239:357-366. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• PETIT PX, ZAMZAMI N, VAYSSIERE J-L et al.: Implication of mitochondria in apoptosis. Mol. Cell. Biochem. (1997) 174:185–188.
   PubMed Web of Science ®Google Scholar
• MCCONKEY DJ, FERNANDEZ A, TRENT II J, ANANTHAS-WAMY HN: Oncogene regulation of endonuclease acti-vation of apoptosis. Cancer Lett. (1995) 94:9–16.
   PubMed Web of Science ®Google Scholar
• MCCARTHY NJ, EVAN GI: Methods for detecting and quantifying apoptosis. Curr. Topics Dev. Biol. (1998) 36:259–278.
   PubMed Web of Science ®Google Scholar
• OBERHAMMER F, WILSON JW, DIVE C et al.: Apoptoticdeath in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internu-cleosomal fragmentation. EMBOJ (1993) 12:3679–3684.
   PubMed Web of Science ®Google Scholar
• ORTH K, O'ROURKE K, SALVESEN GS, DIXIT VM: Molecu-lar ordering of apoptotic mammalian ced-3/ICE-like proteases. J. Biol. Chem. (1996) 271:20977–20980.
   PubMed Web of Science ®Google Scholar
• COHEN GM: Caspases: the executioners of apoptosis. Biochem. J. (1997) 326:1–16.
   PubMed Web of Science ®Google Scholar
• ••This paper systematically reviews what is known about eachof the cysteine proteases (caspases) known to be involved in the execution phase of the apoptotic pathway helping us to make sense of a rapidly expanding class of enzymes.
   Google Scholar
• SULSTON JE, HORVITZ HR: Post-embryonic cell lineagesof the nematode, Caenorhabditis elegans. Dev. (1977) 56:110–156.
   Google Scholar
• KORSMEYER SJ: Bc1-2: an antidote to programmed celldeath. Cancer Surv. (1992) 15:105–118.
   PubMedGoogle Scholar
• YIN XM, OLTVAI ZN, VEIS-NOVACK DJ, LINETTE GP,KORSMEYER SJ: Bc1-2 gene family and the regulation of programmed cell death. Cold Spring Harbor Symp. Quark Biol. (1994) 59:387–393.
   PubMedGoogle Scholar
• BOISE LH, GONZALES-GARCIA M, POSTEMA CE et al.:bcl-x, a bc/-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell (1993) 74:597–608.
   PubMed Web of Science ®Google Scholar
• OLTVAI ZN, MILLIMAN CL, KORSMEYER SJ: Bc1-2 hetero-dimerizes in vivo with a conserved homolog, Box, that accelerates programmed cell death. Cell (1993) 74:609–619.
   PubMed Web of Science ®Google Scholar
• YANG E, ZHA JP, JOCKEL J et al.: Bad, a heterodimericpartner for Bc1-xy and Bc1-2, displaces Box and pro-motes cell death. Cell (1995) 80:285–291.
   PubMed Web of Science ®Google Scholar
• CHITTENDOM T, HARRINGTON EA, O'CONNOR R et al.:Induction of apoptosis by the Bc1-2 homologue Bak. Nature (1995) 374:733–736.
   Google Scholar
• KIEFER MC, BRAUER MJ, POWERS VC et al: Modulation ofapoptosis by the widely distributed bc1-2 homologue Bak. Nature (1995) 374:736–739.
   PubMed Web of Science ®Google Scholar
• FARROW SN, WHITE JHM, MARTINOU I eta].: Cloning of abc1-2 homolog by interaction with adenovirus El B 19 K. Nature (1995) 374:731–733.
   Google Scholar
• KOZOPAS KM, YANG T, BUCHAN HL, ZHOU P, CRAIGRW: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. ScL USA (1993) 90:3516–3520.
   PubMed Web of Science ®Google Scholar
• REYNOLDS JE, YANG T, QIAN LP et al.: Mc1-1, a memberof the Bc1-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Can-cer Res. (1994) 54:6348–6352.
   PubMed Web of Science ®Google Scholar
• GILLET G, GUERIN M, TREMBLEAU A, BRUN G: A Bc1-2-related gene is activated in avian cells transformed by the Rous sarcoma virus. EMBO J (1995) 14:1372–1382.
   PubMed Web of Science ®Google Scholar
• XUE D, SHAHAM S, HORVITZ HR: The Caenorhabditis elegans cell-death protein CED-3 us a cysteine prote-ase with substrate specificities similar to those of the human CPP-32 protease. Genes Dev. (1996) 10:578–591.
   PubMedGoogle Scholar
• ALNEMRI ES, LIVINGSTON DJ, NICHOLSON DW eta].: Hu-man ICE/CED-3 protease nomenclature. Cell (1996) 87:171.
   Google Scholar
• DUAN H, CHINNAIYAN AM, HUDSON PL et al.: ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. Biol. Chem. (1996) 271:1621–1625.
   Web of Science ®Google Scholar
• KAUFMAN SH: Induction of endonucleolytic DNA cleav-age in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic drugs. Cancer Res. (1989) 49:5870–5878.
   PubMed Web of Science ®Google Scholar
• KAUFMAN SH, DESNOYERS S, OTTAVIANO Y, DAVIDSONNE, POIRIER GG: Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. (1993) 53:3976–3985.
   PubMed Web of Science ®Google Scholar
• KUIDA K, LIPPE JA, KU G et al.: Altered cytokine exportand apoptosis inmice deficient in interleukin-1 beta converting enzyme. Science (1995) 267: 2000-2003.
   Google Scholar
• CLEM RJ, FECHHEIMER M, MILLER LK: Prevention of apoptosis by a baculovirus gene during infection of in-sect cells. Science (1991) 254:1388–1390.
   PubMed Web of Science ®Google Scholar
• XUE D, HORVITZ HR: Inhibition of the Caenorhabiditis elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein. Nature (1995) 377:248–251.
   PubMed Web of Science ®Google Scholar
• BUMP NJ, HACKETT M, HUGUNIN M et al.: Inhibition of ICE family proteases by baculovirus antiapoptotic pro-tein p35. Science (1995) 269: 1885-1888.
   Google Scholar
• BEIDLER DR, TEWARI M, FRIESEN PD, POIRIER G, DIXIT VM: The baculovirus p35 protein inhibits Fas- and tu-mor necrosis induced apoptosis. J. Biol. Chem. (1995) 270:16526–16528.
   PubMed Web of Science ®Google Scholar
• BOLDIN MP, GONCHAROV TM, GOLTSEV YV et al.: In-volvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell (1996) 85:803–815.
   PubMed Web of Science ®Google Scholar
• MUZIO M, CHIANNAIYAN AM, KISCHEL FC et al.: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is-recruited to the CD95 (Fas/APO-1) death-inducing sig-naling complex. Cell (1996) 85:817–827.
   PubMed Web of Science ®Google Scholar
• FERNANDES-ALNEMRI T, ARMSTRONG RC, KREBS J et al.: In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6) FADD-like domains. Proc. Natl. Acad. Sci. USA (1996) 93:7464–7469.
   Google Scholar
• ZOU H, HENZEL WJ, LIU X, LUTSCHG A, WANG X: Apaf-1, a human protein homologous to C. elegans ced-4, par-ticipates in cytochrome c-dependent activation of caspase-3. Cell (1997) 90:405–413.
   Google Scholar
• EVAN G, LITTLEWOOD T, HANCOCK D et al.: C-myc: on-cogene and tumor suppressor gene. In: Apoptosis. Mi-hich E, Schimke RT (Eds.), Plenum Press, New York (1994) 63–72.
   Google Scholar
• GREEN DR, MAHBOUBI A, NISHIOKA W et al.: Promotion and inhibition of activation-induced apoptosis in T-cell hybridomas by oncogenes and related signals. Im-munol Rev. (1994) 142:321–342.
   PubMed Web of Science ®Google Scholar
• MORGENBESSER SD, WILLIAMS BO, JACKS T, DEPINHO RA: p53-dependent apoptosis produced by RB-deficiency in the developing mouse lens. Nature (1994) 371:72–74.
   PubMed Web of Science ®Google Scholar
• HORIKOSHI N, USHEVA A, CHEN J et al.: Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S ElA protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell. Biol. (1995) 15:227–234.
   PubMed Web of Science ®Google Scholar
• NEUBAUER A, THIEDE C, HUHN D, WITTIG B: P53 and in-duction of apoptosis as a target for anticancer therapy. Leukemia (1996) 10\(Suppl. 3) :S2–54.
   Google Scholar
• KASTAN MB, ONYEKWERE 0, SIDRANSKY D, VOGEL-STEIN B, CRAIG RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. (1991) 51:6304–6311.
   PubMed Web of Science ®Google Scholar
• LANE DP: p53, a guardian of the genome. Nature (1992) 358:15–16.
   PubMed Web of Science ®Google Scholar
• HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 mutations in human cancer. Science (1991) 253:49–53.
   PubMed Web of Science ®Google Scholar
• FLOMERFELT FA, MIESFIELD RL: Recessive mutations in a common pathway block thymocyte apoptosis in-duced by multiple signals. J. Cell Biol. (1994) 127:1729–1742.
   PubMed Web of Science ®Google Scholar
• WALTON MI, WHYSONG D, O'CONNOR PM et al: Consti-tutive expression of human bc1-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. (1993) 53:1853–1861.
   PubMed Web of Science ®Google Scholar
• REED JC: Bc1-2 and the regulation of programmed cell death.j Cell Biol. (1994) 124:1–6.
   PubMed Web of Science ®Google Scholar
• WANG HG, TAKAYAMA S, RAPP UR, REED JC: Bc1-2 inter-acting protein, BAG-1, binds to and activates the kinase Raf-1. Proc. Natl. Acad. Sci. USA (1996) 93:7063–7068.
   PubMed Web of Science ®Google Scholar
• WANG HG, RAPP UR, REED JC: Bc1-2 targets the protein kinase Raf-1 to mitochondria. Cell (1996) 87:1–20.
   PubMedGoogle Scholar
• DEL PESO L, GONZALES-GARCIA M, PAGE C, HERRERA R, NUNEZ G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 278:687–689.
   PubMed Web of Science ®Google Scholar
• DATTA SR, DUDEK H, TAO X et al.: Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. Cell (1997) 91:231–241.
   PubMed Web of Science ®Google Scholar
• INBAL B, COHEN 0, POLAK-CHARCON S et al.: DAP ki-nase links control of apoptosis to metastasis. Nature (1997) 390:180–183.
   Google Scholar
• BAZZONI F, BEUTLER B: The tumor necrosis factor ligand and receptor families. New Engl. J. Med. (1996) 334:1717-1725. NAGATA S, GOLDSTEIN P: The Fas death factor. Science (1995) 267:1449-1456. CHINNAIYAN AM, O'ROURKE K, TEWARI M, DIXIT VM: FADD, a novel death domain-containing protein, in-teracts with the death domain of Fas and initiates apoptosis. Cell (1995) 81:505–512.
   Google Scholar
• BOLDIN MP, VARFOLOMEEV EE, PANCER Z et al.: A novel protein that interacts with the death domain of Fas/AP01 contains a sequence motif related to the death domain. J. Biol. Chem. (1995) 270:7795–7798.
   PubMed Web of Science ®Google Scholar
• HSU H, XIONG J, GOEDDEL DV: The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell (1995) 81:495–504.
   PubMed Web of Science ®Google Scholar
• STANGER BZ, LEDER P, LEE TH, KIM E, SEED B: RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell (1995) 81:513–523.
   PubMed Web of Science ®Google Scholar
• HSU H, SHU H-B, PAN M-G, GOEDDEL DV: TRADD-TRAF2 and TRADD-FADD interactions define two dis-tinct TNF receptor 1 signal transduction pathways. Cell (1996) 84:299–308.
   PubMed Web of Science ®Google Scholar
• SCHULTE-HERMANN R, BURSCH W, GRASL-KRAUPP B: Active cell death (apoptosis) in liver biology and dis-ease. Prog. Liver Dis. (1995) 13:1–35.
   PubMedGoogle Scholar
• LAFON C, MATHIEU C, GUERRIN M et al.: Transforming growth factor 01-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bc1-2. Cell Growth Diff (1996) 7:1095–1104.
   PubMedGoogle Scholar
• DIVE C, EVANS C, WHETTON A: Induction of apoptosis-new targets for cancer chemotherapy. Sem. Cancer Biol. (1992) 3:417–427.
   PubMedGoogle Scholar
• HICKMAN JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. (1992) 11:121–139.
   PubMed Web of Science ®Google Scholar
• IMAM H, ERIKSSON B, LUKINIUS A et al.: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol. (1997) 36:607–614.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, PARKINSON DR, ITRI L eta].: 13 cis-retinoic acid and interferon-a-2a: effective combination ther-apy for advanced squamous cell carcinoma of the skin. J. Natl. Cancer Inst. (1992) 84:235–241.
   Google Scholar
• LIPPMAN SM, KAVANAUGH JJ, PAREDES-ESPINOZA M et 13-cis-retinoic acid and interferon-a-2a: highly ac-tive systemic therapy for squamous cell carcinoma of the cervix. J. Natl. Cancer Inst. (1992) 84:241-245. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• LIPPMAN SM, KAVANAUGH JJ, PAREDES-ESPINOZA M et 13-cis-retinoic acid plus interferon-a-2a in locally advanced squamous cell carcinoma of the cervix. J. Natl. Cancer Inst. (1993) 85:499–500.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, GLISSON BS, KAVANAUGH JJ et al.: Retinoic acid and interferon combination studies in human cancer. Eur. J. Cancer (1993) 29a (Suppl.):S9–S13.
   Google Scholar
• SUNDARESAN A, CLAYPOOL K, MEHTA K et al.: Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphoma. Cell Growth Diff (1997) 8:1071–1082.
   PubMedGoogle Scholar
• ALDRIDGE DR, ARENDS MJ, RADFORD IR: Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogic survival dose-response. Br. J. Cancer (1995) 71:571–577.
   PubMed Web of Science ®Google Scholar
• FERTIL B, MALAISE EP: Intrinsic radiosensitivity of hu-man cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiat. Oncol Biol. Phys. (1985) 11:1699–1707.
   PubMed Web of Science ®Google Scholar
• KERR JFR, SEARLE J: Apoptosis: its nature and kinetic role. In: Radiation Biology in Cancer Research. Meyn RE, Withers HR (Eds.), Raven Press, New York (1980):367–384.
   Google Scholar
• AMEISEN JC, CAPRON A: Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immu-nol. Today (1991) 12:102–105.
   PubMedGoogle Scholar
• SARIN A, CLERICI M, BLATT SP et al.: Inhibition of activation-induced programmed cell death and resto-ration of defective immune responses of HIV + donors by cysteine protease inhibitors. J. Immunol. (1994) 22:862–872.
   Google Scholar
• BELIKOVA AM, GRINEVA NI, KNORRE DG, MYSINA SD: Specific cleavage of DNA on guanosine residues by 2',3'- 0- [4-(N-2-chloroethyl-N-methylamino)ben-zylidine]uridine and its 5'-methyl-phosphate. Do Acad. Natl. SSSR (1973) 212:876–879.
   Web of Science ®Google Scholar
• LAVROVSKY Y, CHEN S, ROY AK: Therapeutic potential and mechanism of action of oligonucleotides and ribo-zymes. Biochem. Mot. Med. (1997) 62:11–22.
   PubMedGoogle Scholar
• ••An excellent review on several genetic approaches to ther-apy and their current development.
   Google Scholar
• LEONETTI JP, DEGOLS G, CLARENC JP et al.: Cell delivery and mechanism of action of anti-sense oligonucleo-tides. Prog. Nucleic Acid Res. Mot. Biol. (1993) 44:143–166.
   PubMed Web of Science ®Google Scholar
• BISHOP MR, IVERSEN PL, BAYEVER E et al.: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. (1996) 14:1320–1326.
   PubMed Web of Science ®Google Scholar
• ••One of the first clinical trials using antisense oligonucleo-tides for therapy of refractory myelogenous leukaemia.
   Google Scholar
• WEBB A, CUNNINGHAM D, COTTER F et al.: BCL-2 an-tisense therapy in patients with non-Hodgkin's lym-phoma. Lancet (1997) 349:1137–1141.
   PubMed Web of Science ®Google Scholar
• ••This paper was one of the first to use antisense oligonucleo-tide therapy in patients and the first to use an antisense oli-gonucleotide directed against a gene specifically involved in suppressing the apoptotic response. The results presented were extremely encouraging showing both efficacy and safety of the approach.
   Google Scholar
• JAMES HA, GIBSON I: The therapeutic potential of ribo-zymes. Blood (1998) 91:371–382.
   PubMed Web of Science ®Google Scholar
• PERSIDIS A: Ribozyme therapeutics. Nat. Biotech. (1997) 15:921–922.
   PubMed Web of Science ®Google Scholar
• ALTMAN S: Ribonuclease P: an enzyme with a catalytic RNA subunit. Adv. Enzymol. (1996) 62:1–36.
   Google Scholar
• ••1989 Nobel Prize in Chemistry awarded to Thomas Cech(Univ. of CO) and Sidney Altman (Yale Univ) for this work.
   Google Scholar
• CECH TR: Self-splicing and enzymatic activity of an in-tervening sequence RNA from Tetrahymena. New Chem. Int. Engl. (1989) 29:759–768.
   Google Scholar
• ••1989 Nobel Prize in Chemistry awarded to Thomas Cech(Univ. of CO) and Sidney Altman (Yale Univ) for this work.
   Google Scholar
• SYMONS RH: Small catalytic RNAs. Annu. Rev. Biochem. (1992) 61:641–671.
   PubMed Web of Science ®Google Scholar
• BRATTY J, CHARTRAND P, FERBEYRE G, CEDERGREN R: The hammerhead RNA domain, a model ribozyme. Biochim. Biophys. Acta. (1993) 1216:345–359.
   PubMed Web of Science ®Google Scholar
• UHLENBECK OC: A small catalytic oligoribonucleotide. Nature (1987) 328:596–600.
   PubMed Web of Science ®Google Scholar
• JAMES W: The use of ribozymes in gene therapy ap-proaches to AIDS. Recent Results in Cancer Research. (1998) 144:139–146.
   PubMedGoogle Scholar
• KITAJIMA I, HANYU N, KAWAHARA K et al.: Ribozyme-based gene cleavage approach to chronic arthritis as-sociated with human T cell leukemia virus type I. Ar-thritis Rheum. (1997) 40:2118–2127.
   PubMed Web of Science ®Google Scholar
• DORAI T, OLSSON CA, KATZ AE et al.: Development of a hammerhead ribozyme against bc1-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate (1997) 32:246–258.
   Google Scholar
• •This paper illustrates the potential uses for ribozyme-mediated therapy for diseases that have become resistant to conventional therapies through sensitisation by genetic ap-proaches.
   Google Scholar
• COLOMBEL M, SYMMANS F, GIL S et al.: Detection of the apoptosis suppressing oncoprotein bc1-2 in hormone refractory human prostate cancers. Am. J. Pathol. (1993) 143:390–400.
   PubMed Web of Science ®Google Scholar
• MCDONNELL TJ, TRONCOSO P, BRISBAY SM et al.: Ex-pression of the protooncogene bc1-2 in the prostate and its association with the emergence of androgen in-dependent prostate cancer. Cancer Res. (1992) 50:6565–6570.
   Google Scholar
• RAFFO AJ, PERLMAN H, CHEN M-W et al.: Overexpres-sion of bc1-2 protects prostate cancer cells from apop-tosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. (1995) 55:4438–4445.
   PubMed Web of Science ®Google Scholar
• MOELLING K, STRACK B, RADZIWILL G: Signal transduc-tion as target of gene therapy. Recent Results in Cancer Research (1996) 142:63–71.
   PubMedGoogle Scholar
• SETH P, KATAYOSE D, LI Z et al.: A recombinant adeno-virus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene ther-apy approach for drug-resistant cancers. Cancer Gene Ther. (1997) 4:383-390. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• CIRIELLI C, RICCIONI T, YANG C et al.: Adenovirus-mediated gene transfer of wild-type p53 results in melanoma apoptosis in vitro and in vivo. Int. J. Cancer (1995) 63:673–679.
   PubMed Web of Science ®Google Scholar
• NIELSEN LL, DELL J, MAXWELL E et al: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. (1997) 4:129–138.
   PubMed Web of Science ®Google Scholar
• KOCK H, HARRIS MP, ANDERSON SC et al.: Adenovirus-mediated p53 gene transfer suppresses growth of hu-man glioblastoma cells in vitro and in vivo. Int. J. Can-cer (1996) 67:808–815.
   PubMed Web of Science ®Google Scholar
• NGUYEN DM, SPITZ FR, YEN N, CRISTIANO RJ, ROTH JA: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thor. Cardio. Surg. (1996) 112:1372–1377.
   PubMed Web of Science ®Google Scholar
• ESCUDE C, GIOVANNANGELI C, SUN JS et al.: Stable triple helices formed by oligonucleotide N3' - P5' phospho-ramidites inhibit transcription elongation. Proc. Nati Acad. Sci. USA (1996) 93:4365–4369.
   PubMed Web of Science ®Google Scholar
• EBERT 0, FINKE S, SALAHI A et al: Lymphocyte apopto-sis: induction by gene transfer techniques. Gene Ther. (1997) 4:296–302.
   PubMed Web of Science ®Google Scholar